InterMune, Inc. (NASDAQ:ITMN) on 27 May 2014 announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). InterMune Inc (NASDAQ:ITMN) stock performance was -0.88% in last session and finished the day at $39.63. Traded volume was 2.82million shares in the last session and the average volume of the stock remained 3.78million shares. The beta of the stock remained 4.80. InterMune Inc (NASDAQ:ITMN) insider ownership is 0.30%.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), after the big top and breakaway gap a few weeks ago, it coiled very tightly and quietly, and suddenly picked up. It’s been up four days in a row, and on Tuesday, it took out the May 1st 7.65 line, up 48 cents, or 6.38%, on 2.6 million shares, closing at 8.00. It’s a beautiful chart. Looking for something around 11ish. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) rose 6.38 percent to $8.00 Tuesday on volume of 2.69million shares. The intra-day range of the stock was $7.57 to $8.06. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has a market capitalization of $827.24million.

Jefferies Group assumed coverage on shares of China Biologic Products Inc (NASDAQ:CBPO) in a report released on Thursday, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $52.00 price objective on the stock. “CBPO is a leading fully integrated plasma-based supplier in China. In an industry with high entry barriers and limited competition, CBPO is expected to outgrow the market in the next 5 years, given its solid control of plasma supply, comprehensive product portfolio, robust pipeline, and potential M&A. Initiate coverage with BUY and US$52 PT.,” Jefferies Group’s analyst wrote. China Biologic Products Inc (NASDAQ:CBPO)’s stock on May 27, 2014 reported a increase of 3.66% to the closing price of $45.27. Its fifty two weeks range is $19.10 -$45.60. The total market capitalization recorded $1.06billion. The overall volume in the last trading session was 40,092.00million shares. In its share capital, CBPO has 23.44million outstanding shares.

VIVUS, Inc. (NASDAQ:VVUS) announced that a poster describing results of an analysis of the association between weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV and annual concomitant medication costs will be presented at the AACE 23rd Annual Scientific & Clinical Congress at the Paris Las Vegas Hotel, Las Vegas, NV. On Tuesday, shares of VIVUS, Inc. (NASDAQ:VVUS) advanced 0.65% to close the day at $4.67. Company return on investment (ROI) is -42.20% and its monthly performance is recorded as -10.02%. VIVUS, Inc. (NASDAQ:VVUS) quarterly revenue growth is -20.31%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced  that the company is scheduled to present a corporate overview at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at the Grand Hyatt in New York, New York. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was 1.94% in last session and finished the day at $6.31. Traded volume was 3.32million shares in the last session and the average volume of the stock remained 5.50million shares. The beta of the stock remained -0.32. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insider ownership is 0.70%.